Abstract
Parkinson's disease is a neurodegenerative disorder characterized by the presence of tremor at rest, bradykinesia and rigidity as a consequence of the selective loss of dopaminergic neurons of the nigrostriatal pathway. The objective of this theoretical review is to examine the placebo response in Parkinson's disease, compiling the information referring to the studies published from year 2000 until the present time by an electronic search in Medline, Psycinfo and Scopus databases. Results indicate that, although there is usually a clear response to antiparkinsonian medication, showing an improvement of the motor symptoms of the disease, significant improvements have also been observed at the motor level in response to the administration of placebo, although generally these changes are of short duration. Finally, some potential limitations of this review are pointed out, and the importance that the placebo response has both for experimental designs and from the clinical point of view.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
